Chapter 1. Incidence of End Stage Kidney Disease. ANZDATA Registry 37th Annual Report. Data to 31-Dec-2013
|
|
|
- Mae Booth
- 7 years ago
- Views:
Transcription
1 Chapter 1 Incidence of End Stage Kidney Disease th Annual Report Data to 31-Dec-213
2 1-2 Stock and Flow Tables 1.1 and 1.2 show the stock and flow of renal replacement therapy (RRT) patients by country and by state. In in 213 there were 2,544 new RRT patients, with an overall incidence rate of 11 per million population (pmp). This rate has now been stable for several years. In there were 546 new patients (123 pmp). The rate in is subject to more annual variation due to lower numbers. In contrast to incident patients, the number of prevalent patients in each country continues to climb; in at the end of 213 there were 21,47 (928 pmp) patients receiving RRT, and in there were 4,156 (936 pmp). Table 1.1 Stock and Flow Country Event Total New Patients 2431 (112) 2335 (16) 2511 (112) 2573 (113) 2544 (11) Total Transplants 773 (36) 846 (38) 825 (37) 845 (37) 882 (38) - Living Donor Transplants Subsequent Transplants AUSTRALIA Total Deaths Dialysis Patients Transplant Patients Total Prevalent 1851 (853) (872) 1999 (891) 2742 (913) 2147 (928) - Dialysis Patients 1468 (483) 1712 (486) 1154 (495) (55) (59) - Transplant Patients 842 (371) 85 (386) 8855 (396) 9264 (48) 9696 (419) Total New Patients 584 (136) 515 (118) 487 (111) 517 (117) 546 (123) Total Transplants 121 (28) 11 (25) 118 (27) 18 (25) 115 (26) - Living Donor Transplants Subsequent Transplants NEW ZEALAND Total Deaths Dialysis Patients Transplant Patients Total Prevalent 3688 (857) 3832 (881) 3878 (885) 3988 (95) 4156 (936) - Dialysis Patients 2281 (53) 2388 (549) 2392 (546) 2467 (56) 2584 (582) - Transplant Patients 147 (327) 1444 (332) 1486 (339) 1521 (345) 1572 (354)
3 1-3 Table 1.2 Stock and Flow by State and Country 213 State New patients (pmp) Transplant operations (pmp) Deaths - dialysis Deaths - transplant Dialysis dependent (pmp) Functioning transplants (pmp) Total prevalent (pmp) QLD 492 (16) 149 (32) (473) 1879 (44) 479 (877) NSW 783 (16) 288 (39) (58) 2715 (366) 6479 (874) ACT 53 (139) () (755) 233 (611) 521 (1366) VIC 651 (113) 266 (46) (54) 2644 (461) 5536 (965) TAS 44 (86) () (421) 223 (435) 439 (856) SA 165 (99) 81 (48) (451) 97 (581) 1723 (131) NT 85 (351) () (2153) 86 (355) 67 (259) WA 271 (18) 98 (39) (452) 946 (375) 286 (828) Aust 2544 (11) 882 (38) (59) 9696 (419) 2147 (928) NZ 546 (123) 115 (26) (582) 1572 (354) 4156 (936) Incident Patients Incident Rates Figure 1.1 New patients, New Patients and Year NZ New patients, NZ The total numbers of incident patients in and since the beginning of RRT are shown in figure 1.1. The flattening off of incidence in the last decade is apparent compared with the strong growth in the preceding decades. Figure 1.2 presents these data another way, showing the numbers of new patients and change in each country over the last 3 years. Table 1.3 shows the number of new patients (pmp) by state and country over There is substantial variation in incidence rates between states, with the lowest rates in Tasmania (86 pmp in 213) and the highest in the Northern Territory (351 pmp in 213).
4 1-4 Figure New patients New Patients and Change New patients Change from previous year Change from previous year Figure New patients New Patients and Change New patients Change from previous year Change from previous year Table 1.3 RRT Incidence (pmp) State QLD 49 (113) 45 (12) 454 (11) 473 (14) 492 (16) NSW 766 (19) 726 (12) 79 (19) 811 (111) 783 (16) ACT 41 (116) 53 (147) 53 (144) 63 (168) 53 (139) Vic 549 (12) 575 (15) 63 (19) 634 (113) 651 (113) Tas 58 (115) 47 (92) 53 (14) 49 (96) 44 (86) SA 27 (129) 182 (112) 184 (112) 23 (123) 165 (99) NT 72 (319) 65 (283) 82 (355) 98 (415) 85 (351) WA 248 (111) 237 (13) 292 (124) 242 (99) 271 (18) Aust 2431 (112) 2335 (16) 2511 (112) 2573 (113) 2544 (11) NZ 584 (136) 515 (118) 487 (111) 517 (117) 546 (123) Figure 1.3 shows incidence rates by age group, and figure 1.4 shows them by age group and state; the bars represent 95% confidence intervals. Note the different y axes for each state. Figure New patients specific rates - Figure New patients specific rates
5 1-5 Figure Figure NT NSW Figure Figure VIC QLD Figure Figure SA 5 WA
6 1-6 Figure Figure TAS ACT The rates in older patients are shown in table 1.4. Incidence rates for older patients tend to be lower in than in. Finally, table 1.5 further categorises the 213 data by sex. Table 1.4 Incidence (pmp) of ESKD in Older Patients Country (234) 28 (234) 294 (24) 317 (259) 32 (258) (333) 255 (281) 293 (37) 294 (287) 316 (292) (444) 291 (413) 278 (382) 294 (389) 34 (389) (542) 271 (493) 31 (539) 259 (452) 262 (444) (394) 156 (357) 163 (367) 189 (424) 19 (425) (179) 77 (199) 63 (156) 69 (164) 59 (135) (325) 93 (42) 62 (26) 84 (351) 77 (319) (438) 7 (398) 75 (416) 62 (324) 78 (379) (511) 48 (354) 47 (327) 45 (298) 45 (292) (472) 33 (317) 22 (211) 27 (254) 34 (311) (24) 18 (227) 19 (234) 13 (159) 8 (97) (61) 3 (44) 5 (71) 1 (14) 4 (54) Table 1.5 and Sex New Patients 213 Country Sex Total Mean Median F M , New Zealand F M
7 1-7 Late Referral The following figures and tables examine late referral, defined as <3 months between referral and RRT start. Figure 1.5 shows the overall proportion of new patients referred late in and over the last 1 years. There has been a steady decline in both countries. In % of n and 15% of New Zealand new patients were referred late. Rates have fallen in each n state (figure 1.5.2) and in all age groups (figure 1.6), although the data are subject to more variation due to low numbers. Tables 1.6 and 1.7 show late referral rates for new patients over by race and primary renal disease. Rates are similar amongst racial groups but vary substantially between primary renal disease categories; for example in 9% of patients with polycystic kidney disease were referred late, compared with 34% of patients with other diseases. Figure Figure Late referral rates All incident patients Late referral rates by state % referred late % referred late NSW/ACT Vic/Tas QLD SA/NT WA Figure Figure Late referral rates by age Late referral rates by age % referred late % referred late
8 1-8 Table 1.6 Late Referral by Country and Race Country Race Late Not late Not reported Total Caucasian 1899 (2%) 739 (79%) 82 (1%) 929 Aboriginal/TSI 276 (24%) 866 (74%) 3 (3%) 1172 Asian 244 (22%) 871 (78%) 8 (1%) 1123 Māori 35 (27%) 95 (73%) (%) 13 Pacific 69 (27%) 182 (72%) 2 (1%) 253 Other 79 (22%) 272 (75%) 13 (4%) 364 Not reported 6 (1%) 35 (56%) 21 (34%) 62 Total 268 (21%) 963 (78%) 156 (1%) Caucasian 169 (16%) 885 (84%) 4 (%) 158 Asian 29 (13%) 19 (87%) (%) 219 Māori 147 (18%) 663 (81%) 8 (1%) 818 Pacific 94 (18%) 415 (81%) 3 (1%) 512 Other 6 (18%) 28 (82%) (%) 34 Not reported (%) 6 (75%) 2 (25%) 8 Table 1.7 Total 445 (17%) 2187 (83%) 17 (1%) 2649 Late Referral by Country and Disease Country Primary Renal Disease Late Not late Not reported Total GN 59 (22%) 265 (77%) 24 (1%) 2679 Analgesic 32 (18%) 144 (81%) 2 (1%) 178 Polycystic 69 (9%) 75 (9%) 11 (1%) 785 Reflux 43 (14%) 265 (86%) 1 (%) 39 Hypertension 351 (21%) 1351 (79%) 8 (%) 171 Diabetes 792 (18%) 3522 (81%) 33 (1%) 4347 Other 54 (34%) 149 (65%) 2 (1%) 169 Uncertain 18 (27%) 485 (72%) 5 (1%) 67 Not reported 11 (1%) 44 (41%) 52 (49%) 17 Total 268 (21%) 963 (78%) 156 (1%) GN 113 (2%) 459 (8%) 3 (1%) 575 Analgesic 4 (27%) 11 (73%) (%) 15 Polycystic 6 (4%) 13 (94%) 3 (2%) 139 Reflux 7 (15%) 4 (85%) (%) 47 Hypertension 38 (14%) 231 (86%) 1 (%) 27 Diabetes 175 (14%) 181 (86%) 7 (1%) 1263 Other 78 (31%) 169 (68%) 1 (%) 248 Uncertain 22 (26%) 62 (74%) (%) 84 Not reported 2 (25%) 4 (5%) 2 (25%) 8 Total 445 (17%) 2187 (83%) 17 (1%) 2649
9 1-9 Co-morbidities Tables show the co-morbidities at RRT entry of new patients in 213. Notably, patients who have never smoked are in the minority in both countries, and nondiabetics are in the minority in. Trends in the prevalence of these co-morbidities at RRT entry are shown in figures , with the bars representing 95% confidence intervals. The last two years have seen a substantial fall in the number of patients reported as having coronary artery disease in both countries, and in, peripheral vascular disease. Table 1.8 Co-morbidities of New Patients with ESKD 213 Country Status at RRT entry Coronary artery disease Peripheral vascular disease Cerebrovascular disease Chronic lung disease No 1646 (65%) 1991 (78%) 2258 (89%) 2149 (84%) Suspected 141 (6%) 147 (6%) 42 (2%) 78 (3%) Yes 757 (3%) 46 (16%) 244 (1%) 317 (12%) No 381 (7%) 438 (8%) 481 (88%) 465 (85%) Suspected 32 (6%) 23 (4%) 15 (3%) 22 (4%) Yes 133 (24%) 85 (16%) 5 (9%) 59 (11%) Table 1.9 Smoking Status of New Patients with ESKD 213 Country Status at RRT entry N (%) Current 288 (11%) Table 1.1 Diabetes Status of New Patients with ESKD 213 Former 17 (4%) Never 1195 (47%) Country Diabetes at RRT entry N (%) No 1338 (53%) Not reported 54 (2%) Type 1 17 (4%) Current 75 (14%) Type (43%) Former 218 (4%) Never 243 (45%) No 236 (43%) Type 1 2 (4%) Not reported 1 (2%) Type 2 29 (53%)
10 1-1 Figure Comorbid conditions at RRT entry Figure Comorbid conditions at RRT entry % of patients 3 2 % of patients Coronary Peripheral vascular Lung Cerebrovascular 1 Coronary Peripheral vascular Lung Cerebrovascular Suspected cases included Suspected cases included Figure 1.8 Diabetes status at RRT entry 6 % of patients Non-diabetic Type 1 diabetes Type 2 diabetes
11 1-11 Primary Renal Disease The primary renal diseases of new patients over are shown in table Diabetes continues to be the leading cause of ESKD in both countries, followed by glomerulonephritis (table 1.12). Analgesic nephropathy is now a rare cause of ESKD. The other causes from table 1.11 are shown in detail in table There has been a trend towards missing data for primary disease in ; the Registry is actively seeking to address this problem. Table 1.11 Primary Renal Disease of New Patients Country Primary Renal Disease GN 51 (21%) 572 (23%) 522 (2%) 493 (19%) Analgesic 37 (2%) 33 (1%) 4 (2%) 26 (1%) Polycystic 166 (7%) 144 (6%) 137 (5%) 161 (6%) Reflux 6 (3%) 56 (2%) 65 (3%) 48 (2%) Hypertension 321 (14%) 363 (14%) 321 (12%) 359 (14%) Diabetes 83 (36%) 891 (35%) 956 (37%) 887 (35%) Other 289 (12%) 313 (12%) 375 (15%) 364 (14%) Uncertain 131 (6%) 134 (5%) 129 (5%) 132 (5%) Not reported (%) 5 (%) 28 (1%) 74 (3%) Total GN 111 (22%) 115 (24%) 16 (21%) 118 (22%) Analgesic 2 (%) 5 (1%) 5 (1%) 1 (%) Polycystic 18 (3%) 29 (6%) 28 (5%) 3 (5%) Reflux 8 (2%) 9 (2%) 8 (2%) 13 (2%) Hypertension 58 (11%) 51 (1%) 48 (9%) 51 (9%) Diabetes 26 (5%) 25 (42%) 252 (49%) 267 (49%) Other 41 (8%) 52 (11%) 48 (9%) 53 (1%) Uncertain 17 (3%) 21 (4%) 15 (3%) 12 (2%) Not reported (%) (%) 7 (1%) 1 (%) Total
12 1-12 Table 1.12 Glomerulonephritis as Cause of Primary Renal Disease in 213 Primary renal disease Advanced GN (unclassified) 3 4 Extra and intra capillary GN (rapidly progressive) 6 Familial GN (including Alports) 1 2 Focal and segmental proliferative GN Focal sclerosing GN (including hyalinosis) 23 5 GN other (specify) 12 GN with systemic disease 2 1 Goodpasture s with linear IgG and lung haemorrhage 12 4 Henoch-Schonlein purpura 1 1 Membranous GN 22 3 Mesangial proliferative (IgA+) Mesangial proliferative (IgA-) 1 2 Mesangial proliferative (no IF studies) 1 Mesangiocapillary GN (double contour) 1 2 Microscopic polyarteritis 9 1 Presumed GN (no biopsy) Primary focal sclerosing GN/focal glomerular sclerosis Proliferative GN with linear IgG and no lung haemorrhage 6 3 S.L.E Scleroderma 5 Secondary focal sclerosing GN 3 3 Wegener s granulomatosis 19 4 Total
13 1-13 Table 1.13 Miscellaneous Primary Renal Diseases in 213 Primary renal disease Calcineurin inhibitor toxicity 12 Cystinosis 2 Gout 1 Interstitial nephritis 42 4 Lead nephropathy 2 Lithium toxicity 15 2 Loss of single kidney (trauma/surgery) 14 4 Oxalosis 2 Post partum nephropathy 1 Pyelonephritis 5 Renal tuberculosis 1 2 Sarcoidosis 2 Bladder neck obstruction (incl. prostatomegaly) 3 Congenital renal hypoplasia and dysplasia 28 2 Neuropathic bladder 1 1 Obstructed megaureter 3 Obstructive nephropathy 24 3 Other lower urinary tract abnormalities (with secondary reflux) 6 Pelvi-ureteric junction obstruction 1 Posterior urethral valves 7 Spina bifida or myelomeningocoele 1 Ureteric obstructive nephropathy 12 3 Calculi 15 5 Medullary cystic disease 5 1 Cortical necrosis 4 3 Haemolytic uraemic syndrome 9 2 Amyloid disease 25 6 Light chain nephropathy (not malignant) 4 3 Paraproteinaemia (Including Multiple Myeloma) 38 3 Renal cell carcinoma (Grawitz) 16 2 Transitional cell carcinoma urinary tract 4 1 Other (Specify) 6 5 Total
14 1-14 Biopsy rates for primary renal disease are essentially stable in both countries (figure 1.9); the bars show 95% confidence intervals. Figure Figure Biopsy rates 1 Biopsy rates Biopsy rate (%) 5 Biopsy rate (%) Primary disease Glomerulonephritis Type 2 diabetes Primary disease Glomerulonephritis Type 2 diabetes Timing of RRT Start The median egfr at RRT start over time is shown in figure 1.1. In there was a slight trend towards earlier initiation of RRT until 29; since then the median egfr has stabilised, and was 7.2mL/ min/1.73m 2 in 213. In timing of RRT hasn t changed in the last 1 years, with a median egfr at RRT start of 6.3mL/min/1.73m 2 in 213. Figure Figure CKD-EPI egfr (ml/min/1.73m 2 ) egfr at RRT start Median Interquartile range CKD-EPI egfr (ml/min/1.73m 2 ) egfr at RRT start Median Interquartile range
15 Suggested Citation:. 37th Report, Chapter 1: Incidence of End Stage Kidney Disease. and Dialysis and Transplant Registry, Adelaide, Available at: C-\ Royal Adelaide Hospital East Wing 9th Floor North Terrace, Adelaide South 215
survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156
introduction 152 < mortality in high- & low-risk patients 154 < predictors of mortality 156 < impact of anemia & dialysis therapy on mortality 158 < mortality in esrd patients with rare s 16 < expected
Medical Policy Kidney Transplant
Medical Policy Kidney Transplant Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy
END STAGE RENAL DISEASE MEDICAL EVIDENCE REPORT MEDICARE ENTITLEMENT AND/OR PATIENT REGISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES Form Approved CENTERS FOR MEDICARE & MEDICAID SERVICES OMB No. 0938-0046 1. Name (Last, First, Middle Initial) END STAGE RENAL DISEASE MEDICAL EVIDENCE REPORT MEDICARE
Corporate Medical Policy Renal (Kidney) Transplantation
Corporate Medical Policy Renal (Kidney) Transplantation File Name: renal_(kidney)_transplantation Origination: 4/1980 Last Review: 11/2005 Active policy, no longer scheduled for routine literature review.
Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology*
Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology* =Abstracts= Registry committee of Korean Society of Nephrology
renal transplantation: A single-center comparative study
Impact of posterior urethral valves on pediatric renal transplantation: A single-center comparative study BY Mohamed Kamal Gheith, MD Oberarzt die Urologie, Universitätsmedizin Mainz Ass. Prof. of Urology,
CMS Special Open Door Forum
CMS CROWNWeb Application CMS Special Open Door Forum ICD-10 Crosswalk for Diagnosis Codes to Indicate Primary Cause of ESRD July 15, 2015 2pm ET 3pm ET Today s Speakers The Centers for Medicare & Medicaid
Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012
Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012 Types of Care Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate
4/25/2016. Transplant Journey. Objectives. Reason for Transplantation at Mayo Clinic. Mayo Clinic Model of Care
Transplant Journey Lynette Fix, RN, BAN, CCTC Objectives Identify key components of transplant evaluation process Identify the patient follow-up process Describe diseases indicated for transplantation
William B. Schwartz Division of Nephrology Fellowship Training Program Curriculum
William B. Schwartz Division of Nephrology Fellowship Training Program Curriculum Consult/Transplant Servic Patient Care Take medical history Perform physical examination Urinalysis and sediment eval Interpret
THE ROLE OF RENAL BIOPSY IN GLOMERULAR DISEASES DIAGNOSTIC FRANCO FERRARIO FABIO PAGNI
THE ROLE OF RENAL BIOPSY IN GLOMERULAR DISEASES DIAGNOSTIC FRANCO FERRARIO FABIO PAGNI Nephropathology Center San Gerardo Hospital-Monza Milan-Bicocca University Italy Percutaneous Renal Biopsy has a fundamental
Chronic kidney disease hospitalisations in Australia
Chronic kidney disease hospitalisations in Australia 2000 01 to 2007 08 August 2010 Australian Institute of Health and Welfare Canberra Cat. no. PHE 127 The Australian Institute of Health and Welfare is
Diabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1
Chronic Kidney Disease (CKD) Algorithm Chronic Kidney Disease (CKD) Algorithm Page 1 Chronic Kidney Disease (CKD) Algorithm (See NICE Clinical Guideline CG73 1 and Quality Standards 2 ) Who should have
Identifying and treating long-term kidney problems (chronic kidney disease)
Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for
NEPHROLOGY COMMON CLINICAL PRESENTATIONS AND CARDINAL MANIFESTATIONS OF RENAL DISEASES-
NEPHOLOGY OON LINIAL PESENTATIONS AND ADINAL ANIFESTATIONS OF ENAL DISEASES- INITIAL EVALUATION AND DEISION-AKING SKILLS GOAL: The residents will learn the evaluation, diagnosis, and management of patients
Systemic Lupus Erythematosus
Harvard-MIT Division of Health Sciences and Technology HST.021: Musculoskeletal Pathophysiology, IAP 2006 Course Director: Dr. Dwight R. Robinson Systemic Lupus Erythematosus A multi-system autoimmune
Aboriginal and Torres Strait Islander people
Chronic kidney disease in Aboriginal and Torres Strait Islander people 211 Australian Institute of Health and Welfare Canberra Cat. No. PHE 151 The Australian Institute of Health and Welfare is a major
Progressive Care Insurance for life A NEW TYPE OF INSURANCE
Progressive Care Insurance for life A NEW TYPE OF INSURANCE New Progressive Care from Sovereign Progressive Care is a type of insurance that is new to New Zealand. It s not a traditional all-or-nothing
High Blood Pressure and Your Kidneys
American Kidney Fund reaching out giving hope improving lives High Blood Pressure and Your Kidneys reaching out giving hope improving lives High Blood Pressure: The #2 Cause of Kidney Failure Your doctor
Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
Kidney Disease: Key Facts and Figures. September 2010
Kidney Disease: Key Facts and Figures September 2010 ii Kidney Disease Key Facts and Figures Contents Introduction... 1 1 Kidney disease common definitions... 2 1.1 Chronic kidney disease... 2 1.2 Acute
Open the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke
Open the Flood Gates Urinary Obstruction and Kidney Stones Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke Nephrology vs. Urology Nephrologist a physician who has been trained in the diagnosis
information CIRCULAR Coronary heart disease in Queensland Michael Coory, Health Information Centre, Information & Business Management Branch Summary
21 Queensland Government Queensland Health Health Information Centre information CIRCULAR Coronary heart disease in Queensland Michael Coory, Health Information Centre, Information & Business Management
Chronic Kidney Disease and Diabetes
Anyone with diabetes can get kidney disease. Diabetes and high blood pressure are the most common causes of kidney disease, and people often have both. Chronic (long term) kidney disease (CKD) caused by
Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD
Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in
DISEASES OF THE GENITOURINARY SYSTEM
DISEASES OF THE GENITOURINARY SYSTEM NEPHRITIS, NEPHROTIC SYNDROME ANS NEPHROSIS (580 589.9) 580 ACUTE GLOMERULONEPHRITIS 580.0 WITH LESION OF PROLIFERATIVE GLOMERULONEPHRITIS 580.4 WITH LESION OF RAPIDLY
Drug-related hospital stays in Australia 1993 2009
in Australia 1993 29 Prepared by Funded by Amanda Roxburgh and Lucy Burns, National Drug and Alcohol Research Centre the Australian Government Department of Health and Ageing Recommended Roxburgh, A.,
ICD Codes: Utility for Classification of CKD by Severity, Treatment and Diagnosis
ICD Codes: Utility for Classification of CKD by Severity, Treatment and Diagnosis Lesley Stevens MD MS Tufts-New England Medical Center Boston, MA Robert Jakob MD Medical Officer, Classifications and Terminologies
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk Behçet s Disease and the Kidneys How are the kidneys affected by Behçet s disease? Kidney disease
Diabetes and the Kidneys
Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
Council of Ambulance Authorities
Council of Ambulance Authorities Patient Satisfaction Survey 2013 Prepared for: Mojca Bizjak-Mikic Manager, Data & Research The Council of Ambulance Authorities Prepared by: Natasha Kapulski Research Associate
Guideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
Council of Ambulance Authorities
Council of Ambulance Authorities National Patient Satisfaction Survey 2015 Prepared for: Mojca Bizjak-Mikic Manager, Data & Research The Council of Ambulance Authorities Prepared by: Dr Svetlana Bogomolova
GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working
GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National
Heart transplantation
Heart transplantation A patient s guide 1 Heart transplantation Heart transplantation has the potential to significantly improve the length and quality of life for patients with severe heart failure.
Renal Cysts What should I do now?
Renal Cysts What should I do now? Dr Edmund Chiong Asst. Professor & Consultant Department of Urology National University Hospital What are renal cysts? Fluid-filled structures in the kidney that are not
John Sharp, MSSA, PMP Manager, Research Informatics Quantitative Health Sciences Cleveland Clinic, Cleveland, Ohio
John Sharp, MSSA, PMP Manager, Research Informatics Quantitative Health Sciences Cleveland Clinic, Cleveland, Ohio Co-Director BiomedicalResearch Informatics Clinical and Translational Science Consortium
THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR)
THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR) Professor Nico van Zandwijk Director Asbestos Diseases Research Institute US US UK UK COUNTRY NZ CAN COUNTRY NZ CAN AUS AUS Mesothelioma International context
1.17 Life expectancy at birth
1.17 Life expectancy at birth The life expectancy of Aboriginal and Torres Strait Islander males and females for a given period. Data sources Life expectancy estimates for the years 2005 2007 presented
Renal syndromes leading to abnormal kidney function:
Renal syndromes leading to abnormal kidney function: An abnormality in kidney function can be detected by the following: 1) changes in serum creatinine concentration, reflecting changes in GFR 2) abnormalities
PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013
PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013 COVERAGE: A simultaneous or combined pancreas-kidney transplant (SPK) from a cadaver donor or a simultaneous
Australia & New Zealand. Return to Work Monitor 2011/12. Heads of Workers Compensation Authorities
Australia & New Zealand Return to Work Monitor 2011/12 Prepared for Heads of Workers Compensation Authorities July 2012 SUITE 3, 101-103 QUEENS PDE PO BOX 441, CLIFTON HILL, VICTORIA 3068 PHONE +613 9482
why? 75 percent The percentage of healthy individuals over age 40 who will become critically ill at some time in the future. 3
Elite coverage can help protect your savings. USAble Life s 1 coverage helps protect your family from the financial impact that can occur as the result of a heart attack, stroke or even cancer by providing
Phoenix Remembrance Life
Phoenix Remembrance Life W e You Asked New Printer- Friendly Design! D e l i v e r e d Field Underwriting Guide For agent use only. Not for distribution to the public as sales literature. Phoenix Remembrance
New Zealand mortality statistics: 1950 to 2010
Contents New Zealand mortality statistics: 1950 to 2010 Purpose 1 Overview of mortality in New Zealand 2 Deaths, raw numbers and age-standardised rates, total population, 1950 to 2010 2 Death rates from
research report 53 Dental decay among Australian children This report provides information on the dental decay experience of Australian Main findings
AIHW Dental Statistics and Research Unit Research report 53 July 2011 Dental decay among Australian children This report provides information on the dental decay experience of Australian children from
National Key Performance Indicators
National Key Performance Indicators for Aboriginal and Torres Strait Islander primary health care First national results June 212 to June 213 National Key Performance Indicators for Aboriginal and
Renal Blood Flow GFR. Glomerulus Fluid Flow and Forces. Renal Blood Flow (cont d)
GFR Glomerular filtration rate: about 120 ml /minute (180 L a day) Decreases with age (about 10 ml/min for each decade over 40) GFR = Sum of the filtration of two million glomeruli Each glomerulus probably
Cancer in Ireland 2013: Annual report of the National Cancer Registry
Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)
Scottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
DIALYSIS COMPACT. The function, diseases and treatments for the human kidney.
DIALYSIS COMPACT The function, diseases and treatments for the human kidney. Content 3 Editorial 4 What do healthy kidneys accomplish? 5 What causes kidney disease? 6 What effects does kidney disease have?
HYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK
Models of Chronic Kidney Disease Care and Initiation of Dialysis Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Early Crash Landings Talk Outline Pathways & Definitions Guideline recommendations
Home Owners Confidence Boosted as Affordability Improves
JOINT QUARTERLY SURVEY NO.1 JUNE QUARTER Home Owners Confidence Boosted as Affordability Improves e quarter recorded an improvement in housing affordability with the proportion of income required to meet
Submission by. Tatts Lotteries. to the. Productivity Commission s Inquiry into Australia s Gambling Industries. March 2009
Submission by Tatts Lotteries to the Productivity Commission s Inquiry into Australia s Gambling Industries March 2009 Tatts Lotteries is a business unit of Tatts Group Limited and this submission is related
Co-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
Section 8» Incidence, Mortality, Survival and Prevalence
Section 8» Incidence, Mortality, Survival and Prevalence 8.1. Description of Statistics Reported This section focuses on the regional distribution of cancer with data derived from the BC Cancer Registry
Most probable Diagnosis
Most probable Diagnosis Evidence from monitoring Blood Pressure Measured using home monitoring device weekly 165 Peak reading 150 Average reading 130 Min reading Evidence from EMR Family history of Essential
Asteron Lifeguard Enhancements Total and Permanent Disablement (TPD) Stand Alone
Enhancements Total and Permanent Disablement (TPD) Stand Alone Contents 1.0 Summary of changes 2 2.0 Improved Included Benefits 4 2.1 New Permanent Disability Increase Benefit New Trigger Events 4 2.2
LCD for Erythrocyte Sedimentation Rate (ESR)
LCD for Erythrocyte Sedimentation Rate (ESR) Applicable CPT Code(s): 85651 Sedimentation Rate, Erythrocyte; Non-Automated 85652 Sedimentation Rate, Erythrocyte; Automated ICD-9 Codes that Support Medical
Renal Diseases. Ruediger W. Lehrich, M.D. Duke University Medical Center, Division of Nephrology
Renal Diseases Ruediger W. Lehrich, M.D. Duke University Medical Center, Division of Nephrology Disclosures none Learning Objectives Basic review of common renal diseases: Acute renal failure Chronic kidney
Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome
Monday 1 st September, 2014 Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome Dear Healthcare Professional, The Medicines and Healthcare Products Regulatory Agency in
Health expenditure Australia 2011 12: analysis by sector
Health expenditure Australia 2011 12: analysis by sector HEALTH AND WELFARE EXPENDITURE SERIES No. 51 HEALTH AND WELFARE EXPENDITURE SERIES Number 51 Health expenditure Australia 2011 12: analysis by sector
Kidneys. Kidney Failure4. Transplantation
Kidneys & Kidney Failure4 Transplantation This booklet helps you understand the process of transplantation. It defines the criteria for a donor and the recipient. It also clearly explains the concepts
Life insurance how much cover is needed? Fact Sheet - October 2014
Life insurance how much cover is needed? Fact Sheet - October 2014 This fact sheet examines various methods of estimating the level of personal life insurance to be taken by an individual. The calculation
NPDA. National Paediatric Diabetes Audit. National Paediatric Diabetes Audit Report 2013-14. Part 1: Care Processes and Outcomes
NPDA National Paediatric Diabetes Audit National Paediatric Diabetes Audit Report 2013-14 Part 1: Care Processes and Outcomes National Paediatric Diabetes Audit 2013-14 Report 1: Care Processes and Outcomes
Indicator 7: Mortality
Mortality Cancer of the cervix is one of the few cancers for which there is an efficacious screening test for detection of the disease at an early stage, and most deaths due to cervical cancer are potentially
Approach to the Patient with Acute Renal Failure. Michael Ornes Abbott Northwestern Hospital
Approach to the Patient with Acute Renal Failure Michael Ornes Abbott Northwestern Hospital Definition Abrupt decrease in glomerular filtration rate Accumulation of urea and other metabolic byproducts
Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents
Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents Introduction... 2 Specialty Excellence Award Determination... 3 America s 100 Best Hospitals
Housing Affordability Report
Housing Affordability Report JUNE QUARTER Stable market but no reprieve for first home Housing affordability remained relatively steady in the June quarter of with the proportion of income required to
1990 Life Insurance and Diabetes
ADS Position Statements 1990 Life Insurance and Diabetes John Carter, John Greenway, Royal Prince Alfred Hospital, Concord Hospital and Hornsby Hospital, NSW Page 1 LIFE INSURANCE AND DIABETES MELLITUS
Chronic Kidney Disease
Page 1 of 6 Chronic Kidney Disease Chronic kidney disease (CKD) means that your kidneys are not working as well as they once did. Various conditions can cause CKD. Severity can vary but most cases are:
Your Kidneys: Master Chemists of the Body
Your Kidneys: Master Chemists of the Body www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes
A Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
GUIDE. Prepare for Your Phone Interview and Medical Exam.
GUIDE Prepare for Your Phone Interview and Medical Exam. WHAT YOU NEED TO HAVE, KNOW, AND DO. All information gathered during the interview and exam will be shared only with those who need it in order
Living with Kidney Disease A comprehensive guide for coping with chronic kidney disease. 3rd Edition Revised and reprinted April 2013
Living with Kidney Disease A comprehensive guide for coping with chronic kidney disease 3rd Edition Revised and reprinted April 2013 Citation: Ministry of Health and Kidney Health New Zealand. 2013. Living
Statistical appendix. A.1 Introduction
A Statistical appendix A.1 Introduction This appendix contains contextual information to assist the interpretation of the performance indicators presented in the Report. The following four key factors
Accelerated Protection. Do I need Critical Illness insurance?
Accelerated Protection Do I need Critical Illness insurance? Are you prepared? It s a fact of life that we all get sick, and sometimes seriously. The cost of recovery from an illness like cancer or heart
Known Donor Questionnaire
Known Donor Questionnaire Your donor s answers to these questions will provide you with a wealth of information about his health. You ll probably need assistance from a health care provider to interpret
Estimated GFR Based on Creatinine and Cystatin C
Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,
Differential Diagnosis
Differential Diagnosis Limited Scleroderma and Scleroderma-Like Disorders Morphea, or localized Scleroderma, usually begins between the ages of 20 to 50 years as patches of yellowish or ivory-colored rigid,
Critical Illness with Term Assurance
AIG Life Critical Illness with Term Assurance Our comprehensive Critical Illness with Term Assurance delivers more value and quality to the customer and their family than ever before. It is designed to
LCD for Viral Hepatitis Serology Tests
LCD for Viral Hepatitis Serology Tests Applicable CPT Code(s): 86692 Antibody; Hepatitis, Delta Agent 86704 Hepatitis B Core Antibody (HBcAb); Total 86705 Hepatitis B Core Antibody (HBcAb); IgM Antibody
The National Service Framework for Renal Services. Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care
The National Service Framework for Renal Services Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care February 2005 DH INFORMATION READER BOX Policy HR / Workforce Management Planning
Substandard Underwriting Structured Settlements
Substandard Underwriting Structured Settlements Structures 101-Back to Basics February 20-22, 2013 Las Vegas, Nevada Rosemary Brindamour BSN CSSC Chief Medical Underwriter Structured Settlement Underwriting
SUD Life Critical Illness Benefit Rider Sales Brochure
SUD Life Critical Illness Benefit Rider Sales Brochure Health is a concern for all of us. A critical illness not only affects a family emotionally but also economically. SUD Life Critical illness rider
CRITICAL ILLNESS INSURANCE. ExtensiA. The ideal complement to your group insurance
CRITICAL ILLNESS INSURANCE ExtensiA The ideal complement to your group insurance Peace of mind within your reach Today, progress in medicine and breakthroughs in research have significantly extended our
Population prevalence rates of birth defects: a data management and epidemiological perspective
Population prevalence rates of birth defects: a data management and epidemiological perspective Merilyn Riley Abstract The Victorian Birth Defects Register (VBDR) is a population-based surveillance system
Housing Australia factsheet
www.shelter.org.au Housing Australia factsheet A quick guide to housing facts and figures Homelessness There were estimated to be 15,237 people experiencing homelessness on Census night in 211. Page 2
Human Normal Immunoglobulin Solution for Intravenous Infusion.
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM is available in single use bottles of 20 ml, 50 ml, 100 ml and 200 ml. OCTAGAM contains
Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
Type 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care
Southern Derbyshire Shared Care Pathology Guidelines AKI guidelines for primary care Contents: FLOW DIAGRAM: MANAGEMENT OF PATIENTS WITH AKI DETECTED IN PRIMARY CARE...2 FLOW DIAGRAM: POST AKI MANAGEMENT
Limited Pay Policy (L-222B) - Underwriting Guidelines
Limited Pay Policy (L-222B) - Underwriting Guidelines 1 Addiction/Abuser Drug - Past or Present Presently Recovered - AA for last 2 years 2 Aids 3 Alcoholic Presently Recovered - AA for last 2 years 4
Diagnostics: Page 2 of 5
Proteinuria Proteinuria is a condition in which there are increased amounts of protein in the urine. There are a number of different diseases which can result in proteinuria. In the early stages of the
Southern NSW Local Health District: Our Population s Health
Page 1 of 5 This Factsheet summarises a selection of health indicators (health behaviours & risk factors, hospitalisations and deaths) for the of the Southern NSW Local Health District (LHD). Health services